Marshall Wace
RVNC

Marshall Wace’s Revance Therapeutics, Inc. RVNC Stock Holding History

Marshall Wace’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-252,468
Closed -$768K – 3201
2024
Q4 		$768K Sell
252,468
-314,832
-55% -$1.37M ﹤0.01% 1858
2024
Q3 		$2.94M Buy
+567,300
New +$2.82M ﹤0.01% 1220
2024
Q2 		– Sell
-781,223
Closed -$3.84M – 3070
2024
Q1 		$3.84M Buy
+781,223
New +$4.62M 0.01% 1103
2023
Q4 		– Sell
-713,638
Closed -$8.19M – 2693
2023
Q3 		$8.19M Buy
713,638
+623,110
+688% +$12M 0.02% 713
2023
Q2 		$2.29M Buy
+90,528
New +$2.82M ﹤0.01% 1335
2022
Q4 		– Sell
-41,253
Closed -$1.11M – 3520
2022
Q3 		$1.11M Buy
41,253
+24,395
+145% +$495K ﹤0.01% 2357
2022
Q2 		$233K Sell
16,858
-105,740
-86% -$1.63M ﹤0.01% 3114
2022
Q1 		$2.39M Buy
+122,598
New +$1.86M ﹤0.01% 1947
2019
Q2 		– Sell
-30,675
Closed -$483K – 1931
2019
Q1 		$483K Buy
+30,675
New +$532K ﹤0.01% 1146

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's RVNC Position: Q1 2025 in Review

Marshall Wace sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 252,468 shares — an estimated $768K sold.

Marshall Wace first reported a position in RVNC in Q1 2019 and held it in 9 quarters. The position peaked at $8.19M in Q3 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Marshall Wace reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Marshall Wace sold 252,468 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $768K.
  • Marshall Wace first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 9 quarters.
  • Marshall Wace's Revance Therapeutics, Inc. position peaked at $8.19M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Marshall Wace's 13F filing for Q1 2025, filed 15 May 2025.